| Budget Amount *help |
¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2016: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2015: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
|
|---|
| Outline of Final Research Achievements |
EMT plays a fundamental role in the early stages of cancer invasion. E-cadherin is an important regulator of EMT. We identified that DYRK2 regulates E-cadherin expression. Knockdown of DYRK2 promoted EMT and cancer invasion in vitro and in vivo.
Attenuated expression of DYRK2 promotes cancer stem-like traits in vitro, tumourigenesis in vivo, and cancer stem cell population. We found that KLF4 serves as a key molecule controlling DYRK2-mediated cancer stem cell. Reduced DYRK2 expression leads to an increase of KLF4 expression, which induces cancer stem-like properties.
We also found that mTORC1 pathway is activated in DYRK2-depleted cells. The ectopic expression of DYRK2 promoted phosphorylation for the ubiquitination and degradation of mTOR.
|
